Cost-effectiveness of liver transplantation versus last-resort systemic therapy for colorectal liver metastases.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 35576387.
- Also identified by DOI 10.1093/bjs/znac022 and PMC identifier 10364692.
- Licence recorded as CC BY-NC.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This study estimated the cost-effectiveness of liver transplantation in patients with colorectal liver metastases confined to the liver with progressive disease, compared with alternative treatment options: TAS-102, regorafenib, or best supportive care. Using a mathematical simulation model, people’s life expectancy and healthcare costs over 25 years were estimated. Transplanted patients lived for 4.28 years, more than 3 years longer than those who received alternative treatment options. Despite this, the high cost of liver transplantation meant that this treatment was cost-effective only at high willingness-to-pay thresholds.
Medical subject headings
- Colorectal Neoplasms
- Liver Neoplasms
- Liver Transplantation